• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Study targets utility of epithelial thickness mapping

Publication
Article
Digital EditionOphthalmology Times: September 1, 2021
Volume 46
Issue 14

Investigators examine usefulness in refractive surgery evaluations.

In a retrospective evaluation of 100 consecutive patients screened for refractive surgery candidacy, a team of investigators hoped to determine how adding corneal epithelial thickness maps to the process can affect patient screening.

Reviewed by J. Bradley Randleman, MD

In a retrospective evaluation of 100 consecutive patients screened for refractive surgery candidacy, a team of investigators hoped to determine how adding corneal epithelial thickness maps to the process can affect patient screening.

A number of corneal imaging technologies are used to evaluate patients who ask about refractive surgery. It is now possible to add epithelial mapping to the screening process.

Related: Tips to chart a course for safe, effective refractive surgery

The authors routinely use a combination of Scheimpflug tomography and anterior segment optical coherence tomography (AS-OCT) in their practice, but until now had not analyzed what impact occurred with the addition of this epithelial mapping.

Analysis
For each patient, screening was performed based on Scheimpflug tomography, clinical data, and patient history.

Two masked reviewers made a decision on eligibility for corneal refractive surgery and choice of surgery.

The reviewers were then shown the patient’s epithelial thickness maps made from the AS-OCT, and the researchers determined the percentage of screenings that changed after evaluating the epithelial thickness maps, in candidacy for surgery, surgery of choice, and ranking of surgical procedures from most favorable to least favorable.

Results
Following the evaluation of the epithelial thickness maps, candidacy for corneal refractive surgery changed in 17% of patients.

Related: Choroidal hypertransmission defects on en face OCT imaging predict geographic atrophy in patients

Of the patients whose candidacy changed, 58.82% resulted in screening in patients and 41.18% of the changes resulted in screening out patients.

In the subset of patients that remained eligible candidates for surgery, the surgery of choice changed in 20.83% of cases after evaluating the epithelial thickness maps.

The ranking of surgical procedures, from most favorable to least favorable, changed in 36.11% of cases, with 13.89% of patients losing eligibility and 11.11% gaining eligibility, for at least 1 surgical procedure.

In the subset of patients in which eligibility for surgery, surgery of choice, and ranking of surgical procedures from most to least favorable did not change, the epithelial thickness maps increased the reviewers’ confidence in their decision in 49.12% of cases, decreased their confidence in 17.54% of cases, and had no impact on their level of confidence in 33.33% of cases.

Related: Visualization with en face OCT offers value for ophthalmologists

Conclusions
The investigators found that epithelial thickness mapping derived from OCT imaging of the cornea alters candidacy for corneal refractive surgery, as well as choice of surgery, in a substantial percentage of patients.

In addition, they found that epithelial thickness maps result in screening in a slightly larger percentage of patients who can be helped with corneal refractive surgery. Therefore, they deemed it a valuable tool for screening evaluations.

---

J. Bradley Randleman, MD

E: drjbr1@gmail.com 
This article is based on Randleman’s presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting. Randleman has no relevant financial disclosures. This work was supported by Research to Prevent Blindness.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.